rf-fullcolor.png

 

July 31, 2018
by Michael Mezher

FDA FY2019 User Fee Table

The US Food and Drug Administration (FDA) has published the user fee amounts it will collect in FY2019 from the manufacturers of pharmaceuticals, generic drugs, biosimilars, medical devices and outsourcing facilities that produce compounded drugs. The table below lists the fees for each program:

Program: FY2019 FY2018
Prescription Drug User Fee Act (PDUFA VI)    

Applications:

 

 

     Requiring clinical data

$2,588,478

$2,421,495

     Not requiring clinical data

$1,294,239

$1,210,748

Program fee

$309,915

$304,162

Generic Drug User Fee Amendments (GDUFA II)    

Applications:

 

 

     Abbreviated new drug application (ANDA)

$178,799

$171,823

     Drug master file (DMF)

$55,013

$47,829

Facilities:

 

 

     Active pharmaceutical ingredient (API) – Domestic

$44,226

$45,367

     API – Foreign

$59,226

$60,367

     Finished dosage form (FDF) – Domestic

$211,305

$211,087

     FDF – Foreign

$226,305

$226,087

     Contract manufacturing organization (CMO) – Domestic

$70,435

$70,362

     CMO – Foreign

$85,435

$85,362

GDUFA program:

 

 

     Large size operation generic drug applicant

$1,862,167

$1,590,792

     Medium size operation generic drug applicant

$744,867

$636,317

     Small business operation generic drug applicant

$186,217

$159,079

Biosimilar User Fee Amendments (BSUFA II)    

Initial biological product development (BPD)

$185,409

$227,213

Annual BPD

$185,409

$227,213

Reactivation

$370,818

$454,426

Applications:

 

 

     Requiring clinical data

$1,746,745

$1,746,745

     Not requiring clinical data

$873,373

$873,373

     Program

$304,162

$304,162

Medical Device User Fee Amendments (MDUFA IV) Standard Fee (Small Business Fee)  

Premarket application (a PMA submitted under section 515(c)(1) of the FD&C Act (21 U.S.C. 360e(c)(1)), a PDP submitted under section 515(f) of the FD&C Act (21 U.S.C. 360e(f), or a BLA submitted under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262))

$322,147 ($80,537)

$310,764 ($77,691)         

Premarket report (submitted under section 515(c)(2) of the FD&C Act)

$322,147 ($80,537)

$310,764 ($77,691)         

Efficacy supplement (to an approved BLA under section 351 of the PHS Act)

$322,147 ($80,537)

$310,764 ($77,691)         

Panel-track supplement

$241,610 ($60,403)

$233,073 ($58,268)

De novo classification request

$96,644 ($24,161)

$93,229 ($23,307)

180-day supplement

$48,322 ($12,081)

$46,615 ($11,654)

Real-time supplement

$22,550 ($5,638)

$21,753 ($5,438)

510(k) premarket notification submission

$10,953 ($2,738)

$10,566 ($2,642)

30-day notice

$5,154 ($2,577)

$4,972 ($2,486)

513(g) request for classification information

$4,349 ($2,175)

$4,195 ($2,098)

Annual fee type

 

 

     Annual fee for periodic reporting on a class III device

$11,275 ($2,819)

$10,877 ($2,719)

Annual establishment registration fee

$4,884 ($4,884)

$4,624 ($4,624)

Outsourcing Facility Fees    

Qualified small business establishment fee

$5,461

$5,364

Non-small business establishment fee

$18,375

$17,364

Re-inspection fee

$16,382

$16,093

 

Federal Register: PDUFA, GDUFA, BsUFA, MDUFA, Outsourcing Facilities

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.